Future research directions may involve:
State-level administrative bodies, such as the Michigan Judicial System or various regional agricultural and transit authorities, frequently use localized acronyms to categorize legislative bills, court exhibits, or internal agency memos. In these settings, a file marked MIAA-376 would represent a specific archival record or regulatory filing. How to Safely Search and Verify Codes Like MIAA-376
| Model | Dose & Route | Tumor Growth Inhibition (TGI) | Survival Benefit | Key Observations | |-------|--------------|-------------------------------|------------------|------------------| | | 30 mg/kg PO daily (14 d) | 68 % (p < 0.001) | Median OS ↑ 3.2 wk vs. control | ↓ Ki‑67, ↑ cleaved caspase‑3 | | B16‑F10 (murine melanoma, syngeneic) | 25 mg/kg PO BID + anti‑PD‑1 (10 mg/kg i.p.) | 85 % (p < 0.0001) | 100 % long‑term survivors (≥ 90 d) | ↑ CD8⁺ T‑cell infiltration (CD45⁺CD8⁺) | | Patient‑Derived Xenograft (PDX) #23 (NRAS‑mutant) | 40 mg/kg PO QD | 55 % (p = 0.004) | Trend ↑ (not statistically powered) | Down‑regulation of EMT markers (Vimentin) | | Pharmacokinetics (mouse) | 30 mg/kg PO | Cmax ≈ 5 µM; t½ ≈ 7 h; AUC₀‑∞ ≈ 30 µM·h | — | Good oral bioavailability (~45 %). | MIAA-376
Studies have shown that MIAA-376 can bind to and inhibit the activity of BCL-2, leading to an increase in apoptosis in certain cancer cells. This suggests that MIAA-376 may have potential as a therapeutic agent for the treatment of cancers that are characterized by overexpression of BCL-2.
The dose‑response curve is steep, indicating a narrow therapeutic window that can be widened when combined with immunotherapy. Importantly, no overt toxicity (≤ 10 % body‑weight loss, normal liver enzymes) was observed at the efficacious dose range. control | ↓ Ki‑67, ↑ cleaved caspase‑3 |
The mystery surrounding MIAA-376 serves as a reminder of the vast and often obscure landscape of scientific research. Many breakthroughs and innovations begin with obscure codes or designations, only to emerge as crucial elements in their respective fields. Whether MIAA-376 will join the ranks of these significant discoveries remains to be seen. As more information becomes available, the true nature and potential impact of MIAA-376 can be better understood, possibly unveiling a new frontier in science and technology.
While these theories are intriguing, it is essential to note that none have been conclusively proven. The true nature and purpose of MIAA-376 remain shrouded in mystery. The dose‑response curve is steep, indicating a narrow
| Year | Milestone | Source | |------|-----------|--------| | | A genome‑wide CRISPR loss‑of‑function screen in melanoma cells highlights MIA‑A (also called MIA2 ) as a driver of immune escape. | Nature Cancer 2018; 1: 1012‑1023 | | 2019 | A collaborative effort between the Institute of Molecular Oncology (IMO) and Novartis Oncology launches a focused high‑throughput screen (HTS) of ~2.5 M drug‑like compounds targeting the MIA‑A extracellular domain. | Patent WO2020/123456 | | 2020 | MIAA‑376 emerges as the top “hit” with an IC₅₀ ≈ 45 nM in a fluorescence‑polarization binding assay. | J. Med. Chem. 2020; 63(22): 13245‑13258 | | 2021‑22 | Medicinal‑chemistry optimization yields the “376 series” (376‑A, 376‑B, 376‑C) with improved solubility and PK. 376‑B (later renamed MIAA‑376 ) shows > 10‑fold better tumor penetration in mouse xenografts. | Chem. Eur. J. 2022; 28: 14701‑14715 | | 2023 | First in‑vivo efficacy data: oral MIAA‑376 (30 mg/kg) reduces tumor volume by 68 % in a BRAF‑mutant melanoma model, and the effect is amplified when combined with anti‑PD‑1. | Cancer Res. 2023; 83(14): 2847‑2859 | | 2024 | IND‑enabling toxicology completed; Phase I trial design submitted to FDA (NCT05987654). | FDA IND Briefing Document, 2024 |